Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally.
Clovis Oncology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.84|
|52 Week High||US$4.06|
|52 Week Low||US$11.10|
|1 Month Change||12.56%|
|3 Month Change||-18.93%|
|1 Year Change||-30.51%|
|3 Year Change||-85.05%|
|5 Year Change||-86.97%|
|Change since IPO||-61.47%|
Recent News & Updates
Clovis: Compelling With Upcoming Catalysts
After a 25% selloff in the last 6 weeks, Clovis presents a compelling risk/reward ratio with upcoming catalysts in the next 3 months. Athena data is due in September which could move Rubraca into the largest oncology market in its class and make it a potential blockbuster. Targeted radiotherapy is the future of cancer treatment and Clovis is a pioneer in this area with its FAP pipeline. Earnings on August 4 will provide much-needed clarity from management.
|CLVS||US Biotechs||US Market|
Return vs Industry: CLVS underperformed the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: CLVS underperformed the US Market which returned 33.6% over the past year.
Stable Share Price: CLVS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CLVS's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.
Clovis Oncology Fundamentals Summary
|CLVS fundamental statistics|
Is CLVS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLVS income statement (TTM)|
|Cost of Revenue||US$34.47m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.12|
|Net Profit Margin||-197.75%|
How did CLVS perform over the long term?See historical performance and comparison
Is Clovis Oncology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CLVS ($4.84) is trading below our estimate of fair value ($47.25)
Significantly Below Fair Value: CLVS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CLVS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CLVS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CLVS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CLVS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Clovis Oncology forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLVS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLVS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLVS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLVS's revenue (29.7% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: CLVS's revenue (29.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLVS is forecast to be unprofitable in 3 years.
How has Clovis Oncology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLVS is currently unprofitable.
Growing Profit Margin: CLVS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CLVS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.5% per year.
Accelerating Growth: Unable to compare CLVS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: CLVS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Clovis Oncology's financial position?
Financial Position Analysis
Short Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CLVS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CLVS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLVS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CLVS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Clovis Oncology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLVS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLVS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLVS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CLVS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Patrick Mahaffy (58 yo)
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...
CEO Compensation Analysis
Compensation vs Market: Patrick's total compensation ($USD3.23M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.
Experienced Management: CLVS's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: CLVS's board of directors are seasoned and experienced ( 12.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CLVS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.2%.
Clovis Oncology, Inc.'s employee growth, exchange listings and data sources
- Name: Clovis Oncology, Inc.
- Ticker: CLVS
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$573.103m
- Shares outstanding: 118.41m
- Website: https://www.clovisoncology.com
Number of Employees
- Clovis Oncology, Inc.
- 5500 Flatiron Parkway
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 00:52|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.